Latest Articles

Publication Date
All News Scientific
Dr Agustí Garcia on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer - OncLive

Dr Agustí Garcia on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer OncLive

Published: April 21, 2025, 7:21 p.m.
Read Full Article
This Common Period Problem Might Actually Be A Dangerous Ovarian Cyst - Times Now

This Common Period Problem Might Actually Be A Dangerous Ovarian Cyst Times Now

Published: April 21, 2025, 1:30 p.m.
Read Full Article
A Case Series: Activity of Pembro-Lenvatinib in dMMR EC Who Have Not Responded to Pembro-Mono - OncLive

A Case Series: Activity of Pembro-Lenvatinib in dMMR EC Who Have Not Responded to Pembro-Mono OncLive

Published: April 21, 2025, 1:17 p.m.
Read Full Article
Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer - OncLive

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer OncLive

Published: April 21, 2025, 1:17 p.m.
Read Full Article
‘It’s a disaster’: Trans woman who claimed her breastmilk can ‘benefit’ babies feels ‘sexless’ after Supreme Court ruling - MSN

‘It’s a disaster’: Trans woman who claimed her breastmilk can ‘benefit’ babies feels ‘sexless’ after Supreme Court ruling MSN

Published: April 19, 2025, 1:26 a.m.
Read Full Article
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer OncLive

Published: April 18, 2025, 3:54 p.m.
Read Full Article
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.
Read Full Article
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.
Read Full Article
‘It’s a disaster’: Trans woman who claimed her breastmilk can ‘benefit’ babies feels ‘sexless’ after Supreme Court ruling - GB News

‘It’s a disaster’: Trans woman who claimed her breastmilk can ‘benefit’ babies feels ‘sexless’ after Supreme Court ruling GB News

Published: April 17, 2025, 11:02 p.m.
Read Full Article
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!